Search / Trial NCT06234241

Normal Values of Cardiac Measurements by Echocardiography in Chinese Based on Artificial Intelligence

Launched by TIANXIN DONG · Jan 23, 2024

Trial Information

Current as of December 22, 2024

Completed

Keywords

ClinConnect Summary

We will establish normal reference values for the volume, function and strain of various heart chambers of Chinese people based on the recruitment of healthy Chinese subjects.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years; No history or clinical evidence of cardiac, cardiovascular, lung, or kidney disease; No abnormal findings on physical examination, biochemical examination, electrocardiography, or echocardiography.
  • Exclusion Criteria:
  • Hypertension (blood pressure \[BP\] \> 140/80 mmHg) or receiving medication for hypertension; body mass index \> 30 kg/m2; total cholesterol ≥ 6.2 mmol/L, triglyceride ≥ 2.3 mmol/L, or high-density lipoprotein cholesterol \< 1.0 mmol/L; endocrine diseases, such as diabetes mellitus (fasting blood glucose ≥ 7.0 mmol/L), thyroid disease, pheochromocytoma, adrenal insufficiency, and hyperaldosteronism; anemia; abnormal liver function; connective tissue diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, dermatomyositis, and scleroderma; malignancy; current pregnancy or lactation; professional sport activity; and a history of alcoholism.

About Tianxin Dong

Tianxin Dong is a dedicated clinical trial sponsor focused on advancing medical research and innovative therapies. With a commitment to improving patient outcomes, the organization specializes in the development and management of clinical trials across various therapeutic areas. Tianxin Dong prioritizes rigorous scientific methodologies and ethical standards, ensuring compliance with regulatory requirements while fostering collaboration with healthcare professionals and research institutions. Through its strategic approach and expertise, Tianxin Dong aims to contribute significantly to the healthcare landscape by bringing new treatments to market that address unmet medical needs.

Locations

Shenyang, Liaoning, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0